We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from...
It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!). After the establishment rolls out bird-flu for everyone's summer bingo...
Reasons for bullish bias: - Safe entry at LH breakout - Price bounce from support - Bullish divergence - Positive Earnings Here are the recommended trading levels: Entry Level(Buy stop): 68.59 Stop Loss Level: 64.05 Take Profit Level 1: 71.98 Take Profit Level 2: 84.79 Take Profit Level 3: Open
Reasons for bullish bias: - Bounce from strong support - Bullish engulfing candle formed at weekly closing Entry Level(CMP): 75.58 Stop Loss Level: 71.20 Take Profit Level 1: 79.96 Take Profit Level 2: 84.34 Take Profit Level 3: Open
If you haven`t bought GILD before the previous earnings: Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 80usd strike price Calls with an expiration date of 2024-6-21, for a premium of approximately $3.10. If these options prove to be profitable prior to the...
In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival...
GILD is pushing a 6-year resistance line. It broke through for a few days a year ago before being battered back down. Let's see if it'll make the move stick this time.
Monthly chart is setting up nicely. if it takes out 88, ATH should be quick. stop loss: 79
If you haven`t bought GILD on the Remdesivir approval: Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week, I would consider purchasing the 80usd strike price in the money Calls with an expiration date of 2024-1-19, for a premium of approximately $4.25. If these options prove to be profitable...
This trade has multiple patterns on M15, and it is with the trend. All timeframes are overbought and have divergence, this trade should be able to fall to the bottom and maybe even more as it is hitting the H4 moving average and has the strength to fall especially with the news regarding Isreal as of now.
XABCD, ABC patterns at play. Confirmation via eMA, candlestick pattern. Here we go. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is...
Gilead offers a very nice setup here, upside as per the chart. You can expect it to do well during January if it holds over $85.43 for the most part, might consolidate again after February the 1st. Best of luck if taking this one. Cheers, Ivan Labrie.
GILD has been stubborn AF on correcting, it will eventually and likely after my puts expire Jan 20 lol.
GILD has been on a monster run, up one day, up the next and failed to pierce through the triple top. Bio pharma stocks are always difficult both short and long, every time I trade one it's always the last time. LOL $71 gap to fill
REALLY nice bull inside candle at a nice high. After a run up.. This would be VERY interesting short. I have zero issue losing 1R on this trade. However, I did mention in a Forbes article that big pharma is PROB going to be the best performing asset / sector From Oct 2022 to April 2023 (mid term election cycle)
GILD should correct back to $70-73 before any further leg up, further breakout to the upside can happen.
Indeed. B Wave in a zigzag form appears to be completed. We are going down to one extent to another. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line....
05th March 2022 Gilead 56 final support. worth to take risk price between 56-60 TP64 & 68 Nimble safe